Literature DB >> 4571237

Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

M Röllinghoff, B T Rouse, N L Warner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4571237     DOI： 10.1093/jnci/50.1.159

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  19 in total

1.  Current status of immunotherapy.

Authors:  A Coates
Journal:  Drugs       Date:  1974       Impact factor: 9.546

2.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Loss of oncogenicity and concomitant increased immunogenicity of murine plasmacytoma cell lines.

Authors:  G D Sorenson; O S Pettengill; C C Cate
Journal:  Am J Pathol       Date:  1978-03       Impact factor: 4.307

4.  Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

Authors:  L M Weiskirch; Y Bar-Dagan; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

5.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.

Authors:  M M Bartik; B A Baumgartel-Scofield; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.

Authors:  L M Weiskirch; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.

Authors:  M M Bartik; M C Ahn; B A Baumgartel; R L Hendricks; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  Presence of a tumour-inhibiting factor (TIF) in sera from normal but not tumour-bearing mice.

Authors:  B S Kim; D K Chin
Journal:  Immunology       Date:  1980-10       Impact factor: 7.397

10.  Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.

Authors:  L M Weiskirch; B A Baumgartel; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.